{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:54:27Z","timestamp":1788173667266,"version":"build-2803163510"},"reference-count":46,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,5,26]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of botulinum toxin (BTX) for motor dysfunction in Parkinson\u2019s disease (PD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Searches of PubMed, EMBASE and the Cochrane Library, from database inception to 20 October 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Studies reported in English with adult PD patients treated with BTX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Primary outcomes were United Parkinson\u2019s Disease Rate Scale Section (UPDRS) III (or its items) and Visual Analogue Scale (VAS). Secondary outcomes were UPDRS-II (or its items), Freezing of Gait Questionnaire (FOG-Q), Timed Up and Go test (TUG) and treatment-related adverse events (TRAEs). Mean difference (MD) or standardised MD (SMD) before and after treatment with 95% CIs were used for continuous variables and risk ratios (RRs) with 95% CIs was used for TRAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six randomised controlled trials (RCTs) and six non-RCTs (case series) were included (n\n                      <jats:sub>total<\/jats:sub>\n                      =224 participants, n\n                      <jats:sub>RCT<\/jats:sub>\n                      =165). No significant difference was found in pooled results of UPDRS-III (available in four RCTs and two non-RCTs, SMD=\u22120.19, 95%\u2009CI \u22120.98 to 0.60), UPDRS-II (four RCTs and one non-RCT, SMD=\u22120.55, 95%\u2009CI \u22121.22 to 0.13), FOG-Q (one RCT and one non-RCT, SMD=0.53, 95%\u2009CI \u22121.93 to 2.98) or the risk of TRAEs (five RCTs, RR 0.87, 95%\u2009CI 0.37 to 2.01). Significant decreases were found in pooled VAS score (three RCTs and five non-RCTs, MD=\u22122.14, 95%\u2009CI \u22123.05 to \u22121.23) and TUG (MD=\u22122.06, 95%\u2009CI \u22122.91 to \u22121.20) after BTX treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BTX may not be associated with motor symptoms alleviation, although it benefits pain alleviation and functional mobility improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-060274","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T13:34:12Z","timestamp":1686922452000},"page":"e060274","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of botulinum toxin for treating motor dysfunction in patients with Parkinson\u2019s disease: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"13","author":[{"given":"Yuqi","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Neurorehabilitation, China Rehabilitation Research Center, Beijing, China"},{"name":"School of Rehabilitation Medicine, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-1766","authenticated-orcid":false,"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation, China Rehabilitation Research Center, Beijing, China"},{"name":"School of Rehabilitation Medicine, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation, China Rehabilitation Research Center, Beijing, China"},{"name":"School of Rehabilitation Medicine, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation, China Rehabilitation Research Center, Beijing, China"},{"name":"School of Rehabilitation Medicine, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation, China Rehabilitation Research Center, Beijing, China"},{"name":"School of Rehabilitation Medicine, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation, China Rehabilitation Research Center, Beijing, China"},{"name":"School of Rehabilitation Medicine, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation, China Rehabilitation Research Center, Beijing, China"},{"name":"School of Rehabilitation Medicine, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-9133","authenticated-orcid":false,"given":"Wu","family":"Xiaoli","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation, China Rehabilitation Research Center, Beijing, China"},{"name":"School of Rehabilitation Medicine, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation, China Rehabilitation Research Center, Beijing, China"},{"name":"School of Rehabilitation Medicine, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"2025121510401465000_13.6.e060274.1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25945"},{"key":"2025121510401465000_13.6.e060274.2","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13691"},{"key":"2025121510401465000_13.6.e060274.3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5604\/12321966.1232774","article-title":"Motor assessment in Parkinson'S disease","volume":"24","author":"Opara","year":"2017","journal-title":"Ann Agric Environ Med"},{"key":"2025121510401465000_13.6.e060274.4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14737175.2017.1241143","article-title":"Perioperative management of Parkinson\u2019s disease","volume":"17","author":"Akbar","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"2025121510401465000_13.6.e060274.5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lfs.2019.03.057","article-title":"Parkinson's disease: mechanisms, Translational models and management strategies","volume":"226","author":"Raza","year":"2019","journal-title":"Life Sci"},{"key":"2025121510401465000_13.6.e060274.6","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","article-title":"Levodopa in Parkinson\u2019s disease: Current status and future developments","volume":"16","author":"Tambasco","year":"2018","journal-title":"Curr Neuropharmacol"},{"key":"2025121510401465000_13.6.e060274.7","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/toxins9090260","article-title":"Botulinum toxin for the treatment of neuropathic pain","volume":"9","author":"Park","year":"2017","journal-title":"Toxins"},{"key":"2025121510401465000_13.6.e060274.8","first-page":"455","article-title":"Botulinum toxins: pharmacology and its current therapeutic evidence for use","volume":"51","author":"Panicker","year":"2003","journal-title":"Neurol India"},{"key":"2025121510401465000_13.6.e060274.9","doi-asserted-by":"crossref","DOI":"10.3390\/toxins9110370","article-title":"Evidence to use botulinum toxin injections in tension-type headache management: A systematic review","volume":"9","author":"Wieckiewicz","year":"2017","journal-title":"Toxins (Basel)"},{"key":"2025121510401465000_13.6.e060274.10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","article-title":"Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm","volume":"389","author":"Bhidayasiri","year":"2018","journal-title":"Journal of the Neurological Sciences"},{"key":"2025121510401465000_13.6.e060274.11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/jcm8030317","article-title":"Effectiveness of the botulinum toxin for treating Sialorrhea in patients with Parkinson\u2019s disease: A","volume":"8","author":"Ruiz-Roca","year":"2019","journal-title":"JCM"},{"key":"2025121510401465000_13.6.e060274.12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.parkreldis.2016.07.001","article-title":"Drooling in Parkinson\u2019s disease: A randomized controlled trial of Incobotulinum toxin A and meta-analysis of botulinum toxins","volume":"30","author":"Narayanaswami","year":"2016","journal-title":"Parkinsonism & Related Disorders"},{"key":"2025121510401465000_13.6.e060274.13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2019.4565","article-title":"Safety and efficacy of Rimabotulinumtoxinb for treatment of Sialorrhea in adults: A randomized clinical trial","volume":"77","author":"Isaacson","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025121510401465000_13.6.e060274.14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.parkreldis.2019.11.024","article-title":"Long-term incobotulinumtoxinA treatment for chronic Sialorrhea: efficacy and safety over 64 weeks","volume":"70","author":"Jost","year":"2020","journal-title":"Parkinsonism & Related Disorders"},{"key":"2025121510401465000_13.6.e060274.15","first-page":"78","article-title":"A double-blind, randomized, placebo controlled study of botulinum toxin type A for limb pain in advanced Parkinson\u2019s disease","volume":"32","author":"Bruno","year":"2017","journal-title":"Mov Disord"},{"key":"2025121510401465000_13.6.e060274.16","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.mayocp.2017.06.010","article-title":"Botulinum toxin in Parkinson disease tremor: a randomized, double-blind, placebo-controlled study with a customized injection approach","volume":"92","author":"Mittal","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2025121510401465000_13.6.e060274.17","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10120532","article-title":"Spatiotemporal gait analysis and lower limb functioning in foot dystonia treated with botulinum toxin","volume":"10","author":"Datta Gupta","year":"2018","journal-title":"Toxins (Basel)"},{"key":"2025121510401465000_13.6.e060274.18","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"2025121510401465000_13.6.e060274.19","unstructured":"Fahn S , Elton R . Members of the UPDRS development committee. In: Fahn S , Marsden CD , Calne DB , et al ., eds. Recent developments in Parkinson\u2019s disease. Florham Park: Macmillan Health Care Information 1987. n.d.: 153\u20131163."},{"key":"2025121510401465000_13.6.e060274.20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1353-8020(99)00062-0","article-title":"Construction of freezing of gait questionnaire for patients with parkinsonism","volume":"6","author":"Giladi","year":"2000","journal-title":"Parkinsonism & Related Disorders"},{"key":"2025121510401465000_13.6.e060274.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151881","article-title":"Intra-Rater, inter-Rater and test-retest reliability of an Instrumented timed up and go (iTUG) test in patients with Parkinson\u2019s disease","volume":"11","author":"van Lummel","year":"2016","journal-title":"PLoS One"},{"key":"2025121510401465000_13.6.e060274.22","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or Interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025121510401465000_13.6.e060274.23","unstructured":"Higgins JPT , Thomas J , Chandler J , et al . Cochrane Handbook for systematic reviews of interventions version 6.2. Cochrane, 2021. Available: www.training.cochrane.org\/handbook"},{"key":"2025121510401465000_13.6.e060274.24","doi-asserted-by":"crossref","unstructured":"Sterne JAC , Savovi\u0107 J , Page MJ , et al . Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019:l4898. doi:10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"2025121510401465000_13.6.e060274.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2025121510401465000_13.6.e060274.26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias visualization (Robvis): an R package and shiny web App for Visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"2025121510401465000_13.6.e060274.27","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025121510401465000_13.6.e060274.28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-0716-1566-9_3","article-title":"Fixed- and random-effects models","volume":"2345","author":"Kanters","year":"2022","journal-title":"Methods Mol Biol"},{"key":"2025121510401465000_13.6.e060274.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025232","article-title":"Morphine in acute coronary syndrome: systematic review and meta-analysis","volume":"9","author":"Duarte","year":"2019","journal-title":"BMJ Open"},{"key":"2025121510401465000_13.6.e060274.30","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7223"},{"key":"2025121510401465000_13.6.e060274.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111493"},{"key":"2025121510401465000_13.6.e060274.32","unstructured":"Higgins J , Green S . Cochrane Handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. Available: http:\/\/www.cochrane-handbook.org"},{"key":"2025121510401465000_13.6.e060274.33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v049.i05","article-title":"Closing the gap between Methodologists and end-users: R as a computational back-end","volume":"49","author":"Wallace","year":"2012","journal-title":"J Stat Soft"},{"key":"2025121510401465000_13.6.e060274.34","first-page":"CR282","article-title":"Botulinum toxin type B for gait freezing in Parkinson\u2019s disease","volume":"10","author":"Fernandez","year":"2004","journal-title":"Med Sci Monit"},{"key":"2025121510401465000_13.6.e060274.35","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/mds.21694","article-title":"Botulinum toxin treatment of lateral axial dystonia in parkinsonism","volume":"22","author":"Bonanni","year":"2007","journal-title":"Mov Disord"},{"key":"2025121510401465000_13.6.e060274.36","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/mds.21396","article-title":"The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson\u2019s disease: a double blind placebo-controlled pilot study","volume":"22","author":"Gurevich","year":"2007","journal-title":"Mov Disord"},{"key":"2025121510401465000_13.6.e060274.37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2340\/16501977-2094","article-title":"Botulinum toxin for foot dystonia in patients with Parkinson\u2019s disease having deep brain stimulation: A case series and a pilot study","volume":"48","author":"Gupta","year":"2016","journal-title":"J Rehabil Med"},{"key":"2025121510401465000_13.6.e060274.38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/mdc3.12411","article-title":"Outcome on balance and gait following botulinum toxin treatment for striatal foot in Parkinson\u2019s disease","volume":"4","author":"Lindholm","year":"2017","journal-title":"Mov Disord Clin Pract"},{"key":"2025121510401465000_13.6.e060274.39","article-title":"Botulinum toxin treatment of freezing of gait in Parkinson\u2019s disease patients as reflected in functional magnetic resonance imaging of leg movement","volume":"123","author":"Vastik","year":"2016","journal-title":"J Neural Transm"},{"key":"2025121510401465000_13.6.e060274.40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.parkreldis.2018.11.003","article-title":"Botulinum toxin for Pisa syndrome: an MRI-, Ultrasound- and Electromyography-guided pilot study","volume":"62","author":"Artusi","year":"2019","journal-title":"Parkinsonism & Related Disorders"},{"key":"2025121510401465000_13.6.e060274.41","first-page":"2717","article-title":"Effects of botulinum toxin type a on mood and cognitive function in patients with Parkinson's disease and depression","volume":"13","author":"Zhu","year":"2021","journal-title":"Am J Transl Res"},{"key":"2025121510401465000_13.6.e060274.42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1017\/cjn.2021.42","article-title":"Effects of Onabotulinum toxin A on gait in Parkinson\u2019s disease patients with foot dystonia","volume":"49","author":"Huang","year":"2022","journal-title":"Can J Neurol Sci"},{"key":"2025121510401465000_13.6.e060274.43","doi-asserted-by":"publisher","DOI":"10.1038\/nm1001-1144"},{"key":"2025121510401465000_13.6.e060274.44","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000311389.26145.95"},{"key":"2025121510401465000_13.6.e060274.45","article-title":"Efficacy and safety of two incobotulinumtoxinA injection intervals in Cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: phase 4, open-label, randomized, Noninferiority study","volume":"6","author":"Comella","year":"2022","journal-title":"Clin Park Relat Disord"},{"key":"2025121510401465000_13.6.e060274.46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1055\/s-0037-1602246","article-title":"Botulinum toxin therapy for Parkinson\u2019s disease","volume":"37","author":"Wagle Shukla","year":"2017","journal-title":"Semin Neurol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-060274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:40:26Z","timestamp":1765824026000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-060274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,16]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/bmjopen-2021-060274"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-060274","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}